Key Opinion Leader conference call with Dr. Harrison from the University of Oxford, UK to discuss Phase 2a HERALD Study of ALG-055009 in MASH (metabolic dysfunction-associated steatohepatitis) will be held on March 7 at 4 pm. Webcast Link
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on ALGS:
- Aligos Therapeutics to Announce 4th Quarter 2023 Financial Results on March 12, 2024
- Aligos Therapeutics, Inc. (ALGS) Q4 Earnings Cheat Sheet
- Aligos Therapeutics Launches Stock Option Exchange Program
- Aligos Therapeutics To Participate in the Leerink Partners Global Biopharma Conference 2024
- Aligos Therapeutics to Host KOL Event to Discuss Phase 2a HERALD Study of ALG-055009 in MASH on March 7, 2024
